SYNDAX PHARMACEUTICALS INC's ticker is SNDX and the CUSIP is 87164F105. A total of 66 filers reported holding SYNDAX PHARMACEUTICALS INC in Q2 2017. The put-call ratio across all filers is - and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $19,763,029 | -28.5% | 1,360,920 | +3.0% | 0.00% | -33.3% |
| Q2 2023 | $27,650,692 | +6.6% | 1,321,103 | +7.6% | 0.00% | 0.0% |
| Q1 2023 | $25,926,940 | +92426.8% | 1,227,601 | +11.5% | 0.00% | -25.0% |
| Q4 2022 | $28,021 | -99.9% | 1,101,029 | +13.7% | 0.00% | 0.0% |
| Q3 2022 | $23,264,000 | +33.2% | 968,129 | +6.6% | 0.00% | +33.3% |
| Q2 2022 | $17,467,000 | +17.5% | 907,856 | +6.1% | 0.00% | +50.0% |
| Q1 2022 | $14,867,000 | -11.2% | 855,415 | +11.9% | 0.00% | 0.0% |
| Q4 2021 | $16,737,000 | +19.5% | 764,627 | +4.3% | 0.00% | 0.0% |
| Q3 2021 | $14,011,000 | +15.4% | 733,220 | +3.7% | 0.00% | 0.0% |
| Q2 2021 | $12,138,000 | -4.2% | 706,942 | +24.7% | 0.00% | 0.0% |
| Q1 2021 | $12,676,000 | +23.1% | 566,923 | +22.4% | 0.00% | 0.0% |
| Q4 2020 | $10,301,000 | +69.4% | 463,176 | +12.4% | 0.00% | +100.0% |
| Q3 2020 | $6,081,000 | -1.0% | 412,013 | -0.6% | 0.00% | 0.0% |
| Q2 2020 | $6,145,000 | +68.1% | 414,690 | +24.4% | 0.00% | 0.0% |
| Q1 2020 | $3,655,000 | -30.6% | 333,258 | -44.5% | 0.00% | 0.0% |
| Q4 2019 | $5,270,000 | +146.5% | 600,402 | +109.8% | 0.00% | – |
| Q3 2019 | $2,138,000 | -14.5% | 286,238 | +6.6% | 0.00% | -100.0% |
| Q2 2019 | $2,500,000 | +141.1% | 268,557 | +35.9% | 0.00% | – |
| Q1 2019 | $1,037,000 | -35.3% | 197,606 | -45.2% | 0.00% | – |
| Q4 2018 | $1,602,000 | +14.3% | 360,398 | +107.8% | 0.00% | – |
| Q3 2018 | $1,401,000 | +18.5% | 173,431 | +3.0% | 0.00% | – |
| Q2 2018 | $1,182,000 | -46.2% | 168,391 | +9.0% | 0.00% | -100.0% |
| Q1 2018 | $2,199,000 | +63.6% | 154,556 | +0.7% | 0.00% | – |
| Q4 2017 | $1,344,000 | -12.0% | 153,483 | +17.4% | 0.00% | -100.0% |
| Q3 2017 | $1,528,000 | -13.2% | 130,680 | +3.7% | 0.00% | 0.0% |
| Q2 2017 | $1,760,000 | +29.7% | 125,999 | +27.3% | 0.00% | 0.0% |
| Q1 2017 | $1,357,000 | +111.4% | 98,962 | +10.5% | 0.00% | – |
| Q4 2016 | $642,000 | -51.3% | 89,552 | +2.9% | 0.00% | -100.0% |
| Q3 2016 | $1,319,000 | +347.1% | 87,035 | +190.3% | 0.00% | – |
| Q2 2016 | $295,000 | – | 29,979 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Aisling Capital Management LP | 1,025,000 | $24,631,000 | 16.36% |
| Kynam Capital Management, LP | 2,272,915 | $54,618,000 | 11.51% |
| Frazier Life Sciences Management, L.P. | 3,412,838 | $82,010,000 | 6.32% |
| Foresite Capital Management IV, LLC | 690,000 | $16,581,000 | 5.33% |
| Paradigm Biocapital Advisors LP | 1,085,142 | $26,076,000 | 3.48% |
| ACUTA CAPITAL PARTNERS, LLC | 324,614 | $7,800,000 | 3.36% |
| COMMODORE CAPITAL LP | 738,110 | $17,737,000 | 2.85% |
| SPHERA FUNDS MANAGEMENT LTD. | 822,696 | $19,769,000 | 2.74% |
| Avidity Partners Management LP | 5,586,900 | $134,253,000 | 2.73% |
| HealthCor Management, L.P. | 859,240 | $20,648,000 | 2.58% |